2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-105418
    WIN-63291 144967-96-4 98%
    WIN-63291 is a selective and orally active phosphodiesterase (PDE) III inhibitor. WIN-63291 can be used for the research of cardiovascular disease.
    WIN-63291
  • HY-105419
    KP-19 145730-95-6 98%
    KP-19 is a Propranolol (HY-B0573B) analogue. KP-19 can be used for the research of cardiovascular disease.
    KP-19
  • HY-105431
    ASI-222 59006-00-7 98%
    ASI-222 is an aminosugar cardiac glycoside. ASI-222 can inhibit Na+/K+ ATPase and show positive inotropic effect. ASI-222 can be used for the research of cardiovascular disease.
    ASI-222
  • HY-105440
    LY 301875 154668-27-6 98%
    LY 301875 is a potent and orally active angiotensin II receptor type 1 (AT1) antagonist with a pKB value of 9.6.
    LY 301875
  • HY-105453
    PD 121981 114785-18-1 98%
    PD 121981 is a angiotensin II receptor antagonist. PD 121981 can be used for the research of cardiovascular disease.
    PD 121981
  • HY-105466
    P-1060 60559-94-6 98%
    P-1060 is a potassium channel opener. P-1060 can be used for the research of cardiovascular disease.
    P-1060
  • HY-105482
    BMY 20844 124886-01-7 98%
    BMY 20844 is an orally active platelet cAMP phosphodiesterase inhibitor with anti-thrombosis activity. BMY 20844 can elevate cAMP levels and activate protein kinase in platelets. BMY 20844 can be used for the research of cardiovascular disease.
    BMY 20844
  • HY-105501
    KI 1769 133300-00-2 98%
    KI 1769 is a potassium channel opener. KI 1769 can exhibit vasodilating effect. KI 1769 prolongs the micturition interval and reduces the resistance to fluid infusion through the urethral lumen. KI 1769 can be used for the research of cardiovascular disease.
    KI 1769
  • HY-105503
    SQ 33800 138447-68-4 98%
    SQ 33800 is a potent inhibitor of human renin with an IC50 of 0.35 nM. SQ 33800 can be used for the research of cardiovascular disease.
    SQ 33800
  • HY-105504
    CI-986 130116-16-4 98%
    CI-986 is a dual inhibitor of COX and 5-LOX. CI-986 can prevent the coronary vasoconstriction and the increased production of LTB(4) and LTC(4). CI-986 also has anti-inflammatory and analgesic effects. CI-986 can be used for the researches of inflammation and cardiovascular disease, such as arthritis.
    CI-986
  • HY-105506
    EXP-7711 114798-27-5 98%
    EXP-7711 is a non peptide angiotensin II (Ang II) AT1 receptor antagonist. EXP-7711’s affinity for wild-type AT1 receptor (Ki =180 nM) is lower than peptide antagonists, but higher than losartan (Ki = 12 nM). EXP-7711 can be used for research on cardiovascular conditions.
    EXP-7711
  • HY-105514
    KP-10614 130273-99-3 98%
    KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research.
    KP-10614
  • HY-105515
    TJN 220 118160-59-1 98%
    TJN 220 is a synthetic derivative of orally active tetrandrine (HY-13764). TJN 220 has a long-lasting and stable antihypertensive effect in various hypertension models. TJN 220 is suitable for controlling nighttime hypertension and does not cause reflex tachycardia. TJN 220 can be used for research on hypertension.
    TJN 220
  • HY-105562
    Nadoxolol 54063-51-3 98%
    Nadoxolol is a non-selective β-adrenaline receptor blocker that can be used in the study of arrhythmias. .
    Nadoxolol
  • HY-105572
    Moveltipril calcium 85921-53-5 98%
    Moveltipril calcium (MC-838 calcium) is an orally active angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moveltipril calcium binds via a stable thioester bond and exhibits relative resistance to enzymatic hydrolysis in rat liver homogenate. Moveltipril calcium effectively inhibits ACE extracted from rabbit lung in a concentration-dependent manner. Moveltipril calcium is able to highly specifically inhibit the contractile response to angiotensin-I (AI) in free rat aortic rings and guinea pig ileum preparations, while enhancing the contractile response to calcitonin.
    Moveltipril calcium
  • HY-105647
    Ambuphylline 5634-34-4 98%
    Ambuphylline (Bufylline) is a bronchodilator. Ambuphylline is a theophylline derivative possibly acting through phosphodiesterase inhibition. Ambuphylline can be used for the research of asthma and other lung diseases.
    Ambuphylline
  • HY-10564S
    Sarpogrelate-d3 hydrochloride 98%
    Sarpogrelate-d3 (hydrochloride) is the deuterium labeled Sarpogrelate hydrochloride. Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis.
    Sarpogrelate-d3 hydrochloride
  • HY-105651
    Butalamine 22131-35-7 98%
    Butalamine is a vasodilator.
    Butalamine
  • HY-105666
    TGX-155 351071-90-4 98%
    TGX-155 (AZ12649385) is a selective inhibitor of PI3Kβ. TGX-155 has potential applications in antithrombotic therapy.
    TGX-155
  • HY-105686
    FR-229934 799841-02-4 98.65%
    FR-229934 is a PDE V inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction.
    FR-229934
Cat. No. Product Name / Synonyms Application Reactivity